We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Show more
Avalo acquires Phase 2-ready anti-IL-1Ξ² mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3...
0001534120false00015341202024-01-302024-01-30UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the...
0001534120false12/3100015341202023-12-282023-12-28UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of...
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Companyβs common stock, par value...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 15.175 | 339.485458613 | 4.47 | 20.38 | 4.43 | 609754 | 4.75072503 | CS |
4 | 15.135 | 335.587583149 | 4.51 | 20.38 | 4.2835 | 179365 | 4.81618866 | CS |
12 | 11.865 | 152.506426735 | 7.78 | 20.38 | 3.9501 | 89473 | 4.99207325 | CS |
26 | -15.875 | -44.6931306306 | 35.52 | 45.096 | 3.9501 | 22141928 | 26.26513453 | CS |
52 | -397.955 | -95.2957375479 | 417.6 | 1130.4 | 3.9501 | 23257469 | 33.55825535 | CS |
156 | -669.155 | -97.1479384437 | 688.8 | 1711.2 | 3.9501 | 9167773 | 39.4516355 | CS |
260 | -669.155 | -97.1479384437 | 688.8 | 1711.2 | 3.9501 | 9167773 | 39.4516355 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions